News

2022/12/23
TAGCyx will be attending 41st Annual J.P. Morgan Healthcare Conference
2022/10/31
Announcement of presentation at the 43rd Annual Meeting of the Japanese Society for Apheresis (November 12, 2022)
2022/09/08
CAGE Bio, TAGCyx and PeptiStar announce execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
2022/07/13
‘The 3rd Aptamer Seminar in Tokyo ~virtual meeting~’ will be held on September 2, 2022.
2022/03/23
TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).
2021/10/08
We will have a booth V2 at Japan Healthcare Venture Summit Oct 13th-15th
2021/09/16
Prof. Masanori Matsumoto at Department of Blood Transfusion Medicine, Nara Medical University will give a lecture on the collaboration project at a symposium of The 83rd Annual Meeting of Japanese Society of Hematology (JSH) (September 23-25, virtual)
2021/09/16
Monasterium laboratory and TAGCyx will present the results of Alopecia Areata project at 2021 European Society for Dermatological Research (ESDR) Annual Meeting (September 22-25, virtual, poster presentation）
2021/08/19
Results of collaboration project with Prof. Sakamoto Lab (Chiba Institute Technology) will be presented at 22nd International Society of Magnetic Resonance Conference, the 9th Asia-Pacific NMR Symposium, the 60th Annual Meeting of the Nuclear Magnetic Resonance Society of Japan (2021), and the 60th Annual Meeting of the Society of Electron Spin Science and Technology
2021/08/10
Pipeline is updated
2021/07/07
TAGCyx raises approximately 210 million JPY
2021/06/04
‘The 2nd Aptamer Seminar in Tokyo ~virtual meeting~’ will be held on July 9, 2021.
2021/04/21
We will be presenting Alopecia Areata project at Society for Investigative Dermatology conference (May 3rd-8th on-line）
2021/04/20
Patent “Method for stabilizing DNA aptamer” is granted in EU.
2021/03/22
Prof. Shinsuke Sando at　THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®
2021/03/05
TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
2021/02/19
Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®
2020/11/29
Our collaborator, Ms. Yuri Hayata of Prof. Sando Lab (The University of Tokyo) obtained poster award at the Chemical Society of Japan, CSJ Chemistry Festa 2020
2020/11/25
SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY
2020/11/17
Showa Denko Materials and the Drug Development Startup TAGCyx Sign a Commissioned Development Agreement on Regenerative Medicine Technologies
2020/10/17
Patent “DNA aptamer capable of bonding to VWF” is granted in the USA.
2020/09/25
Ms. Yukari Ikeda received the Seven Star Pharmacist candidate Award for the results of skin penetration of our anti-IFNγ aptamer.
2020/09/18
TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases.
2020/09/04
Results of collaboration project with Prof. Sando Lab (The University of Tokyo) will be presented at the Chemical Society of Japan, CSJ Chemistry Festa 2020
2020/09/03
Patent “Method for stabilizing functional nucleic acids” is granted in Europe.
2020/08/24
Ms. Yukari Ikeda will present data of skin penetration of our anti-IFNγ aptamer at the 36th Annual Meeting of the Japan Society of Drug Delivery System on August 28th 2020
2020/06/22
We updated in-house pipeline
2020/06/01
TAGCyx established an Audit & Supervisory Board
2020/05/28
Notice of New management team
2020/05/26
Patent “DNA aptamer capable of bonding to VWF” is granted in Japan.
2020/05/05
TAGCyx raises approximately 200 million JPY
2020/02/19
TAGCyx and GC Pharma has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004
2019/12/25
TAGCyx receives milestone payment for collaborative research with HEALIOS K.K.
2019/10/10
TAGCyx enters into a collaborative aptamer glycosylation research agreement with GlyTech, Inc.
2019/10/09
TAGCyx has executed a collaborative antibody-aptamer conjugate research agreement with Chiome Bioscience Inc.
2019/09/19
Aptamer Seminar in Tokyo will be held
2018/10/04
Collaborator, Dr. Kazuya Sakai will present data of anti-von Willerbrand Factor A1 domain Xenoligo at the American Society of Hematology
2018/10/04
TAGCyx will be presenting at Japan Healthcare Venture Summit 2018 at Yokohama
2018/09/28
Dr. Kazuya Sakai will present data of our anti-coagulant aptamer at the 80th Annual Meeting of the Japanese Society of Hematology on Oct 13th 2018
2018/09/28
TAGCyx has executed collaborative research agreement with HEALIOS K.K.
2018/04/29
Completion of 500 million JPY Series B financing
2017/10/23
Oct 16th We have moved to Tokyo University Komaba campus.
2017/10/07
Presentation schedule in November
2017/10/07
Presentation schedule in October
2017/02/01
TAGCyx has executed a research and development collaboration agreement with a European biopharma company in February. The partnership will continue for 2 years which is extendable with mutual agreement and will apply the TAGcyx platform towards the identificatio
2016/08/31
TagCyx announces the completion of 500 million Japanese Yen (US$ 4.9 Million, as of Aug. 31, 2016) private financing, led by The University of Tokyo Edge Capital as a lead investor, and SMBC Venture Capital, Nissay Capital CO., LTD. (Aug 2016)

TAGCyx Biotechnologies

Headquarter

Tokyo University Komaba Open Laboratory #403, 4-6-1 Komaba, Meguro-ku, Tokyo 153-0041, Japan